Cargando…

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature

The optimal second- and third-line chemotherapy and targeted therapy for patients with advanced esophagogastric cancer is still a matter of debate. Therefore, a literature search was carried out in Medline, EMBASE, CENTRAL, and oncology conferences until January 2016 for randomized controlled trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	ter Veer, Emil, Haj Mohammad, Nadia, van Valkenhoef, Gert, Ngai, Lok Lam, Mali, Rosa M. A., van Oijen, Martijn G. H., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035657/ https://www.ncbi.nlm.nih.gov/pubmed/27417221 http://dx.doi.org/10.1007/s10555-016-9632-2

Ejemplares similares

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2016)

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
por: Haj Mohammad, N., et al.
Publicado: (2015)

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
por: ter Veer, Emil, et al.
Publicado: (2018)

The Use of (Network) Meta-Analysis in Clinical Oncology
por: ter Veer, Emil, et al.
Publicado: (2019)

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy
por: Kuijper, Steven C., et al.
Publicado: (2022)

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
por: Pape, Marieke, et al.
Publicado: (2023)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands
por: Pape, Marieke, et al.
Publicado: (2023)

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
por: Kroese, Tiuri E., et al.
Publicado: (2022)

COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022)

Feasibility of CT radiomics to predict treatment response of individual liver metastases in esophagogastric cancer patients
por: Klaassen, Remy, et al.
Publicado: (2018)

The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer
por: Doeve, Benthe H., et al.
Publicado: (2023)

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
por: Stroes, Charlotte I, et al.
Publicado: (2022)

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
por: van den Boorn, Héctor G., et al.
Publicado: (2019)

Influence of second-generation and third-generation mobile phones on critical care medical equipment
por: Van Lieshout, E, et al.
Publicado: (2006)

Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study
por: van de Water, Loïs F, et al.
Publicado: (2021)

Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis
por: Augustinus, Simone, et al.
Publicado: (2023)

Genotyping and outcomes of presumptive second line ART failure cases switched to third line or maintained on second line ART in Mumbai, India
por: Gill, Naresh, et al.
Publicado: (2019)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Previously unidentified duplicate registrations of clinical trials: an exploratory analysis of registry data worldwide
por: van Valkenhoef, Gert, et al.
Publicado: (2016)

Deficiencies in the transfer and availability of clinical trials evidence: a review of existing systems and standards
por: Valkenhoef, Gert van, et al.
Publicado: (2012)

The association between wearable activity monitor metrics and performance status in oncology: a systematic review
por: Kos, Milan, et al.
Publicado: (2021)

Real-life introduction of powered circular stapler for esophagogastric anastomosis: cohort and propensity matched score study
por: Vanstraelen, Stijn, et al.
Publicado: (2022)

Automated generation of node‐splitting models for assessment of inconsistency in network meta‐analysis
por: van Valkenhoef, Gert, et al.
Publicado: (2015)

Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study
por: Luijten, J. C. H. B. M., et al.
Publicado: (2022)

Oncologic Feasibility of Proximal Gastrectomy in Upper Third Advanced Gastric and Esophagogastric Junctional Cancer
por: Yun, Won-Gun, et al.
Publicado: (2021)

It is time to consider third-line options in antiretroviral-experienced paediatric patients?
por: van Zyl, Gert U, et al.
Publicado: (2011)

Rapid stromal remodeling by short‐term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2020)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India
por: Khan, Samsuddin, et al.
Publicado: (2014)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa
por: Onoya, Dorina, et al.
Publicado: (2017)

ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ulaibl4hvia5poer290ti927fv